% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • joynlight77 joynlight77 Jan 17, 2013 11:04 AM Flag

    A great addition to your portfolio along with CLSN. Key Milestones here.

    OncoSec (ONCS)- Innovative biotech to consider in addition to CLSN.

    Key milestones that OncoSec looks forward to accomplishing for 2013 include:

    Present interim response data from OncoSec's Phase II melanoma trial along with long-term progression-free survival (PFS) data from its previous Phase I melanoma program

    Present final data from OncoSec's Phase II melanoma trial and Merkel cell carcinoma trial

    Conduct an end-of-Phase II meeting with the FDA for OncoSec's melanoma and Merkel cell carcinoma program

    Present interim data from OncoSec's Phase II cutaneous T-cell lymphoma program

    Plan to launch a pivotal Merkel cell carcinoma program

    Plan to launch a Phase IIB metastatic melanoma program

    OncoSec also reviewed the significant achievements of the company during the past year.

    2012: Initiated Three Phase II trials with Patients Now Enrolling in Eight Centers of Excellence Across North America

    2012: Presented Positive Interim Data

    2012: Secured New Patents, Certification and In-licensing

1.085-0.005(-0.46%)1:16 PMEDT